Itepekimab Phase 3 COPD Trial for 1239 Patients Reaches Primary Completion

The Phase 3 trial for itepekimab (SAR440340) in patients with chronic obstructive pulmonary disease (COPD) reached its primary completion on April 21, 2025. This significant milestone indicates that data collection for the primary endpoint has concluded for the study, which enrolled 1239 participants.

Background

Itepekimab is under investigation as a potential therapeutic agent for chronic obstructive pulmonary disease (COPD), a prevalent and progressive inflammatory lung disease characterized by persistent respiratory symptoms and airflow limitation. COPD is a leading cause of morbidity and mortality globally, impacting millions of individuals. While existing treatments focus on symptom management and reducing the frequency of exacerbations, there remains an unmet medical need for novel therapies that can effectively alter disease progression or significantly improve outcomes for specific patient populations, such as former smokers with moderate-to-severe disease.

Trial design

The study, officially registered as NCT04751487, is a Phase 3, randomized, placebo-controlled clinical trial. It is titled 'Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)'. The trial successfully enrolled a total of 1239 participants. The investigation specifically targeted former smokers diagnosed with moderate-to-severe COPD. Participants were randomized to receive either itepekimab (SAR440340) or a placebo. The primary objective of the study was to evaluate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate-or-severe COPD exacerbations within this primary population. Key secondary objectives included assessing the efficacy of itepekimab on pulmonary function and the overall occurrence of acute exacerbation of COPD (AECOPD).

What this means

The primary completion of this pivotal Phase 3 trial for itepekimab marks a crucial advancement in its development for COPD. With the collection of data for the primary endpoint now finalized, the focus shifts to the rigorous analysis of the extensive dataset. This analysis will thoroughly assess the efficacy, safety, and tolerability profile of itepekimab in comparison to placebo. The forthcoming results from this large-scale study are highly anticipated by the medical community, as they will provide essential insights into itepekimab's potential to reduce exacerbations and improve lung function in former smokers with moderate-to-severe COPD, potentially influencing future treatment strategies for this challenging condition.

Source

The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The event for study NCT04751487, titled 'Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)', was recorded with a primary completion date of April 21, 2025 on clinicaltrials.gov.